Propensity-Score Matched Comparison of Midterm Angiographic Outcomes of Sirolimus- Versus Everolimus- and Biolimus-Eluting Stents for De Novo Coronary Stenosis
| Autor: | Chikara Mori, Tetsuya Ishikawa, Kenichiro Suzuki, Takayuki Ogawa, Koichi Hashimoto, Hiroshi Sakamoto, Kimiaki Komukai, Michihiro Yoshimura, Takeyuki Kubota, Makoto Mutoh |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Coronary stenosis 030204 cardiovascular system & hematology Coronary Angiography law.invention 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Randomized controlled trial law Internal medicine Daily practice medicine Humans Everolimus 030212 general & internal medicine Clinical efficacy Propensity Score Aged Retrospective Studies Sirolimus Surrogate endpoint business.industry Coronary Stenosis Drug-Eluting Stents General Medicine Coronary Vessels Treatment Outcome Propensity score matching Cardiology Female Cardiology and Cardiovascular Medicine business Immunosuppressive Agents Follow-Up Studies medicine.drug |
| Zdroj: | International Heart Journal. 58:320-327 |
| ISSN: | 1349-3299 1349-2365 |
| DOI: | 10.1536/ihj.16-360 |
| Popis: | We conducted propensity-score matched comparisons of midterm angiographic outcomes of sirolimus (SES) versus either everolimus- (EES) or biolimus- (BES) eluting stents after placements for coronary stenosis in a daily practice environment since previous randomized trials did not demonstrate the superiority of EES and BES over SES in terms of midterm angiographic outcomes.The present study was a non-randomized, retrospective, and lesion-based study, recruiting angiographically followed-up lesions within 550 days after successful and elective SES (n = 1793), EES (n = 1303), or BES (n = 324) placement for de novo native coronary stenosis during the period from August 2004 to January 2014 at 6 institutes. The endpoint, as an angiographic surrogate marker of clinical efficacy, was the distribution of in-stent follow-up percent diameter stenosis (%DS) which comprised the percentages of 1) follow-up %DS20 and 2) follow-up %DS50. Propensityscore matched analyses were conducted to adjust 21 baselines.In 1215 baseline adjusted lesions, the endpoints in the EES group [1) 74.1%, and 2) 4.6%] were significantly different from those in the SES group [57.9%; P0.001, 7.2%; P = 0.006, respectively). In 307 baseline adjusted lesions, the endpoints in the BES group [1) 80.5%, 2) 2.0%] were significantly different from those in the SES group [59.3%; P0.001, 2) 8.1%; P = 0.001, respectively].The present study is the first to confirm the superiority of midterm angiographic outcomes after the placement of EES and BES over SES for de novo coronary stenosis in a clinical setting. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|